Dyspepsia prevalence in general population aged over 20 in the west part of Iran

Department of Internal Medicine, Kurdistan University of Medical Sciences, Besat Hospital, Keshavarz Ave, Sanandaj, Iran.
Journal of the Pakistan Medical Association (Impact Factor: 0.41). 07/2012; 62(7):672-6.
Source: PubMed


To estimate the prevalence of dyspepsia in the general population aged over 20 in western Iran.
The cross-sectional study was conducted among the randomly selected general population over the age of 20 years in Sanandaj city. Iran, from April to December 2009. A questionnaire containing demographic, symptoms and history variables was used. Dependent variables were self-reported gastrointestinal symptoms. The prevalence of dyspepsia in different groups was analysed using chi square test, while logistic regression analysis was done to determine dyspepsia, ulcer-like, dysmotility-like and reflux-like prevalence after controlling the confounders.
Among 590 respondents, the prevalence of dyspepsia was 54.6% (n = 322). Among them were 243 (41.2%) cases of uninvestigated dyspepsia. According to dyspepsia classification, the prevalence of ulcer-like, dysmotility-like, reflux-like and non-specific dyspepsia were 31.5% (n = 186), 11% (n = 65), 27.3% (n = 161) and 12.4% (n = 74), respectively. Difference in dyspepsia prevalence between men and women persisted after adjustment for other factors (p =0.01) and dyspepsia prevalence was higher in over-60-years old group than the middle aged group (p = 0.008). CONCLUSIONn: The study showed high prevalence of dyspepsia in the general population. Gender, age, family history and theophylline consumption affect the prevalence of dyspepsia.

1 Follower
6 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives Many cross-sectional surveys have reported the prevalence of uninvestigated dyspepsia, but there has been no recent systematic review of data from all studies to determine its global prevalence and risk factors. Design MEDLINE, EMBASE and EMBASE Classic were searched (until January 2014) to identify population-based studies that reported the prevalence of uninvestigated dyspepsia in adults (≥15 years old); dyspepsia was defined using symptom-based criteria or questionnaires. The prevalence of dyspepsia was extracted for all studies and according to the criteria used to define it. Pooled prevalence, according to study location and certain other characteristics, ORs and 95% CIs were calculated. Results Of the 306 citations evaluated, 103 reported the prevalence of uninvestigated dyspepsia in 100 separate study populations, containing 312 415 subjects. Overall pooled prevalence in all studies was 20.8% (95% CI 17.8% to 23.9%). The prevalence varied according to country (from 1.8% to 57.0%) and criteria used to define dyspepsia. The greatest prevalence values were found when a broad definition of dyspepsia (29.5%; 95% CI 25.3% to 33.8%) or upper abdominal or epigastric pain or discomfort (20.4%; 95% CI 16.3% to 24.8%) were used. The prevalence was higher in women (OR 1.24; 95% CI 1.13 to 1.36), smokers (OR 1.25; 95% CI 1.12 to 1.40), non-steroidal anti-inflammatory drug (NSAID) users (OR 1.59; 95% CI 1.27 to 1.99) and Helicobacter pylori-positive individuals (OR 1.18; 95% CI 1.04 to 1.33). Conclusions The overall pooled prevalence of uninvestigated dyspepsia was 21%, but varied among countries and according to the criteria used to define its presence. Prevalence is significantly higher in women, smokers, NSAID users and H. pylori-positive individuals, although these associations were modest.
    Gut 08/2014; 64(7). DOI:10.1136/gutjnl-2014-307843 · 14.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Functional dyspepsia (FD) is a common gastrointestinal disease that is highly prevalent worldwide. Because of its heterogeneous pathophysiology, treatment options for FD can be difficult to choose; in this context, complementary and alternative medicine modalities have been suggested as promising options. To evaluate the efficacy of a traditional Persian medicine, jollab, in reducing patients' FD symptoms. In a double-blind randomized clinical trial, 160 patients with a diagnosis of FD were enrolled and treated with either jollab or placebo (15ml, t.i.d., four weeks, orally). The outcomes reported were changes in symptom frequency and severity as recorded in patients' diaries and evaluated with the Short Form of the Leeds Dyspepsia Questionnaire (SF-LDQ), and physical examination. The response rate was higher in the treatment group (78%) than in the placebo group (31%) according to per-protocol sample analysis (P < .001). Symptoms of FD disappeared significantly more frequently, and the rate of concomitant synthetic drug consumption was significantly lower, in the jollab group compared to the placebo group at the end of the trial. Mean total symptom frequency and severity according to the SF-LDQ score was 1.55 ± 2.78 in the treatment group versus 5.61 ± 3.80 in the placebo group at the last follow-up time point (P < .001). A promising safety profile for jollab was observed throughout the trial. In patients with FD, jollab appeared to be more effective than the placebo. Complementary and alternative therapies such as the use of this traditional medicinal substance may be beneficial in relieving symptoms of dyspepsia [ACTRN12613000584730]. Copyright © 2015 Elsevier Inc. All rights reserved.
    EXPLORE The Journal of Science and Healing 02/2015; 11(3). DOI:10.1016/j.explore.2015.02.007 · 1.00 Impact Factor

Similar Publications